Semaglutide vs Retatrutide: How the Two Drugs Compare

Feature	Semaglutide	Retatrutide
Receptor targets	GLP-1 only	GLP-1 + GIP + glucagon
Status	FDA approved	Investigational
Administration	Weekly injection or oral	Weekly injection
Peak trial weight loss	~15% (STEP-1, 68 wk)	~28% (TRIUMPH-1, 80 wk)
Cardiovascular outcomes	Proven (SELECT)	Not yet reported
Available to patients today	Yes, by prescription	No legal human-use form
Maker	Novo Nordisk	Eli Lilly

Semaglutide is a mature, approved medicine. Novo Nordisk’s GLP-1 agonist has been approved for type 2 diabetes since 2017 (Ozempic), for obesity since 2021 (Wegovy), and as an oral weight-loss formulation since December 2025. Retatrutide is an Eli Lilly investigational compound still in its Phase 3 TRIUMPH program, with no approval in any country. The two sit at opposite ends of the GLP-1 development arc: one is years into real-world use, the other is the leading next-generation candidate. Full profiles of each sit in our full guide to semaglutide and full guide to retatrutide. Both belong to the wider drug class covered in our GLP-1 agonists and fat-loss peptides overview.

The bottom line: semaglutide is a prescription medicine with years of real-world use, while retatrutide is an experimental compound that has not been approved or made available by prescription.

The clearest difference is how many systems each drug engages. Semaglutide activates a single receptor, GLP-1, which reduces appetite, slows gastric emptying and stimulates glucose-dependent insulin secretion. Retatrutide activates three receptors at once: GLP-1 and GIP, the two incretin pathways that act on appetite and insulin, plus glucagon.

That glucagon arm is the conceptual dividing line between the two drugs. A GLP-1 agonist like semaglutide works almost entirely by reducing calories taken in. Adding glucagon receptor agonism brings a second lever: glucagon raises energy expenditure and promotes breakdown of fat in the liver, so the body burns more rather than only eating less. Combining a “calories out” mechanism with the “calories in” mechanisms is the main reason a triple agonist has produced larger trial weight loss than single or dual agonists.

The bottom line: semaglutide pulls one lever, appetite, while retatrutide adds energy expenditure through glucagon, which raises both its efficacy ceiling and its side-effect burden.

The headline numbers favour retatrutide, but the maturity of the evidence favours semaglutide, and that distinction matters as much as the raw figures.

Semaglutide has a deep, peer-reviewed record built over years. The STEP-1 obesity trial produced about 14.9% weight loss at 68 weeks, and the landmark SELECT trial showed a roughly 20% reduction in major adverse cardiovascular events, the first such outcome for an obesity medicine. These are published, fully reported trials with long follow-up.

Retatrutide’s numbers are larger but earlier-stage. In TRIUMPH-1, its first dedicated obesity Phase 3 trial, reported on 21 May 2026, the 12 mg dose produced about 28.3% mean weight loss at 80 weeks on the efficacy estimand, with 45.3% of that group losing at least 30% of their body weight. Participants with a baseline BMI of 35 or higher who continued treatment reached up to 30.3% at 104 weeks. Supporting trials point the same way: TRIUMPH-4 (December 2025) showed about 28.7% weight loss with marked osteoarthritis pain relief, and TRANSCEND-T2D-1 (March 2026) showed 16.8% at 40 weeks in type 2 diabetes. These remain topline or single-trial results, no cardiovascular outcome data exist yet, and full peer-reviewed publication and detailed presentation were expected at the American Diabetes Association meeting in June 2026.

Trial	Drug	Weight loss	Evidence tier
STEP-1	Semaglutide 2.4 mg	~14.9% (68 wk)	Published Phase 3
SELECT	Semaglutide 2.4 mg	~20% fewer cardiac events	Published outcomes trial
TRIUMPH-1	Retatrutide 12 mg	~28.3% (80 wk)	Topline Phase 3
TRIUMPH-1 extension	Retatrutide 12 mg	~30.3% (104 wk, BMI 35+)	Topline extension
TRIUMPH-4	Retatrutide 12 mg	~28.7% (68 wk)	Phase 3 (osteoarthritis)

The bottom line: retatrutide has produced roughly double semaglutide’s weight loss in trials, but semaglutide is backed by mature, peer-reviewed evidence including proven cardiovascular benefit.

For anyone weighing the two, availability is the decisive practical difference. Semaglutide can be prescribed today, as a weekly injection or an oral tablet, through normal medical channels, with branded list prices that remain high but are increasingly offset by cash-pay and insurance options. The wider oral GLP-1 market has also expanded now that the small-molecule pill orforglipron is approved, adding lower-cost competition at the entry end.

Retatrutide has no approved human-use form at any price. It cannot be obtained through a pharmacy or a prescriber, only as a “research use only” compound that is not authorised for human use and carries no guarantee of identity, purity or dose. So the cost comparison is not a like-for-like price contest; it is a choice between a regulated medicine you can actually obtain and a compound that has no legal route to a patient.

Region	Semaglutide	Retatrutide
United States	Approved	Not approved
UK and EU	Approved	Not approved
Australia	Approved	Not approved

Retatrutide is available only as a research-use-only compound, which is not authorised for human use. Lilly is expected to file for approval around late 2026 to early 2027, once further diabetes and cardiovascular readouts are complete, so the earliest realistic approval would follow that.

Both compounds share the GLP-1 class profile of mostly gastrointestinal side effects and a thyroid C-cell tumour signal seen in rodents. The difference is in degree and in how well characterised each is. Semaglutide’s safety is established across years of use and large outcome trials. Retatrutide’s trials report higher rates of gastrointestinal effects, with the top dose in TRIUMPH-1 producing nausea in roughly 42%, diarrhoea in about 32%, vomiting in about 25% and constipation in about 26% of participants, most of it mild to moderate. It also produces dose-dependent increases in heart rate linked to its glucagon activity, and its long-term safety is not yet established.

The bottom line: both are mostly gastrointestinal in their side effects, but semaglutide’s profile is well mapped while retatrutide’s is heavier and still being characterised.

Because only one of these drugs is actually available, the practical comparison is lopsided. For someone who needs treatment now, semaglutide is a real, regulated option with known dosing, a long safety record and proven cardiovascular benefit, and it remains a sensible benchmark whether taken by injection or as a tablet. Retatrutide is not a current option for anyone outside a clinical trial, because it has no approved human-use form anywhere.

Retatrutide’s interest is as a future prospect. Its trial weight loss is the largest yet reported for this class, so if it is approved and its longer-term safety holds up, it could raise the ceiling on what pharmacological weight loss can achieve. Until then, the honest framing is proven and available today versus more powerful on paper but not yet a choice patients can make.

Is retatrutide better than semaglutide for weight loss?

Retatrutide produced close to double semaglutide’s trial weight loss in its first dedicated obesity study, but it is investigational and unapproved, while semaglutide is an approved medicine with proven cardiovascular benefit.

What is the difference between semaglutide and retatrutide?

Semaglutide targets one receptor (GLP-1), whereas retatrutide targets three (GLP-1, GIP and glucagon), and the added glucagon activity is why retatrutide drives larger weight loss.

Is retatrutide FDA approved?

No. Retatrutide is investigational and not approved in any country as of 2026; an FDA filing is expected around late 2026 to early 2027.

When will retatrutide be available?

No date is set. Lilly is expected to file for approval around late 2026 to early 2027 after further trial readouts, so any approval and launch would come after that review.

Can you buy retatrutide?

Retatrutide is sold only as a research-use-only compound, which is not authorised for human use and carries unverified identity, purity and dosing.